PROS1 and COVID-19: Here, we have evaluated the immunogenicity and efficacy in mice of three MVA-based vaccine candidates against COVID-19, expressing either a native non-stabilized or a prefusion-stabilized SARS-CoV-2 S protein, when administered as a single dose by the IN route.